References(42)
[1]
van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet 2017, 390(10107): 2084-2098.
[2]
Gruzman A, Wood WL, Alpert E, et al. Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosis. PNAS 2007, 104(30): 12524-12529.
[3]
Barber SC, Shaw PJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med 2010, 48(5): 629-641.
[4]
Taylor JP, Brown RH Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature 2016, 539(7628): 197-206.
[5]
Canosa A, Grassano M, Barberis M, et al. A familial amyotrophic lateral sclerosis pedigree discordant for a novel p.Glu46Asp heterozygous OPTN variant and the p.Ala5Val heterozygous SOD1 missense mutation. J Clin Neurosci 2020, 75: 223-225.
[6]
Trias E, Kovacs M, King PH, et al. Schwann cells orchestrate peripheral nerve inflammation through the expression of CSF1, IL-34, and SCF in amyotrophic lateral sclerosis. Glia 2020, 68(6): 1165-1181.
[7]
Liu J, Wang F. Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications. Front Immunol 2017, 8: 1005.
[8]
Gourie-Devi M, Panda S, Sharma A. Sleep disorders in amyotrophic lateral sclerosis: a questionnaire- based study from India. Neurol India 2018, 66(3): 700.
[9]
Bishir M, Bhat A, Essa MM, et al. Sleep deprivation and neurological disorders. Biomed Res Int 2020, 2020: 5764017
[10]
Eijk RPAV, Eijkemans MJC, Nikolakopoulos S, et al. Pharmacogenetic interactions in amyotrophic lateral sclerosis: a step closer to a cure? Pharmacogenomics J 2020, 20(2): 220-226.
[11]
Decker H, Piermartiri TCB, Nedel CB, et al. Guanosine and GMP increase the number of granular cerebellar neurons in culture: dependence on adenosine A2A and ionotropic glutamate receptors. Purinergic Signal 2019, 15(4): 439-450.
[12]
Ottestad-Hansen S, Hu QX, Follin-Arbelet VV, et al. The cystine-glutamate exchanger (xCT, Slc7a11) is expressed in significant concentrations in a subpopulation of astrocytes in the mouse brain. Glia 2018, 66(5): 951-970.
[13]
Foran E, Trotti D. Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis. Antioxid Redox Signal 2009, 11(7): 1587-1602.
[14]
Zhong Z, Deane R, Ali Z, et al. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat Neurosci 2008, 11(4): 420-422.
[15]
Winkler EA, Sengillo JD, Sagare AP, et al. Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. PNS 2014, 111(11): E1035-E1042.
[16]
Gabel S, Koncina E, Dorban G, et al. Inflammation promotes a conversion of astrocytes into neural progenitor cells via NF-kappaB activation. Mol Neurobiol 2016, 53(8): 5041-5055.
[17]
Livne-Bar I, Wei J, Liu HH, et al. Astrocyte-derived lipoxins A4 and B4 promote neuroprotection from acute and chronic injury. J Clin Invest 2017, 127(12): 4403-4414.
[18]
Hooten KG, Beers DR, Zhao W, et al. Protective and toxic neuroinflammation in amyotrophic lateral sclerosis. Neurotherapeutics 2015, 12(2): 364-375.
[19]
Jha MK, Jo M, Kim JH, et al. Microglia-astrocyte crosstalk: an intimate molecular conversation. Neuroscientist 2019, 25(3): 227-240.
[20]
Mashima K, Takahashi S, Minami K, et al. Neuroprotective role of astroglia in parkinson disease by reducing oxidative stress through dopamine- induced activation of pentose-phosphate pathway. ASN Neuro 2018, 10: 1759091418775562.
[21]
Dávila D, Fernández S, Torres-Alemán I. Astrocyte resilience to oxidative stress induced by insulin-like growth factor I (IGF-I) involves preserved AKT (protein kinase B) activity. J Biol Chem 2016, 291(5): 2510-2523.
[22]
Atalaia A, de Carvalho M, Evangelista T, et al. Sleep characteristics of amyotrophic lateral sclerosis in patients with preserved diaphragmatic function. Amyotroph Lateral Scler 2007, 8(2): 101-105.
[23]
Carratù P, Cassano A, Gadaleta F, et al. Association between low sniff nasal-inspiratory pressure (SNIP) and sleep disordered breathing in amyotrophic lateral sclerosis: Preliminary results. Amyotroph Lateral Scler 2011, 12(6): 458-463.
[24]
Iber C, Ancoli-Israel S, Chesson A, et al. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specification. 1st ed. Westchester: American Academy of Sleep Medicine, 2007, pp 134-137.
[25]
Arnulf I, Similowski T, Salachas F, et al. Sleep disorders and diaphragmatic function in patients with amyotrophic lateral sclerosis. Am J Respir Crit Care Med 2000, 161(3 Pt 1): 849-856.
[26]
Vrijsen B, Testelmans D, Belge C, et al. Non- invasive ventilation in amyotrophic lateral sclerosis. Amyotroph La Scl Fr 2013, 14(2): 85-95.
[27]
Anafi RC, Kayser MS, Raizen DM. Exploring phylogeny to find the function of sleep. Nat Rev Neurosci 2019, 20(2): 109-116.
[28]
Fultz NE, Bonmassar G, Setsompop K, et al. Coupled electrophysiological, hemodynamic, and cerebrospinal fluid oscillations in human sleep. Science 2019, 366(6465): 628-631.
[29]
Irwin MR. Sleep and inflammation: partners in sickness and in health. Nat Rev Immunol 2019, 19(11): 702-715.
[30]
Bellemsi M, de Vivo L, Chini M, et al. Sleep loss promotes astrocytic phagocytosis and microglial activation in mouse cerebral cortex. J Neurosci 2017, 37(21): 5263-5273.
[31]
Bakour C, Schwartz S, O’Rourke K, et al. Sleep duration trajectories and systemic inflammation in young adults: results from the national longitudinal study of adolescent to adult health (add health). Sleep 2017, 40(11): zsx156.
[32]
Maurovich-Horvat E, Pollmächer TZ, Sonka K. The effects of sleep and sleep deprivation on metabolic, endocrine and immune parameters. Prague Med Rep 2008, 109(4): 275-285.
[33]
Piovezan RD, Abucham J, Dos Santos RV, et al. The impact of sleep on age-related sarcopenia: Possible connections and clinical implications. Ageing Res Rev 2015, 23(Pt B): 210-220.
[34]
Sifringer M, von Haefen C, Krain M, et al. Neuroprotective effect of dexmedetomidine on hyperoxia-induced toxicity in the neonatal rat brain. Oxid Med Cell Longev 2015, 2015: 530371.
[35]
Wang SL, Duan L, Xia B, et al. Dexmedetomidine preconditioning plays a neuroprotective role and suppresses TLR4/NF-κB pathways model of cerebral ischemia reperfusion. Biomed Pharmacother 2017, 93: 1337-1342.
[36]
An JX, Williams JP, Fang QW, et al. Feasibility of patient-controlled sleep with dexmedetomidine in treating chronic intractable insomnia. Nat Sci Sleep 2020, 12: 1033-1042.
[37]
Akeju O, Hobbs, LE Gao, et al. Dexmedetomidine promotes biomimetic non-rapid eye movement stage 3 sleep in humans: A pilot study. Clin Neurophysiol 2018, 129(1): 69-78.
[38]
Alexopoulou C, Kondili E, Diamantaki E, et al. Effects of dexmedetomidine on sleep quality in critically ill patients: a pilot study. Anesthesiology 2014, 121(4): 801-807.
[39]
Gerashchenko D, Pasumarthi RK, Kilduff TS. Plasticity-related gene expression during eszopiclone- induced sleep. Sleep 2017, 40(7): zsx098.
[40]
Kurian KM, Forbes RB, Colville S, et al. Cause of death and clinical grading criteria in a cohort of amyotrophic lateral sclerosis cases undergoing autopsy from the Scottish Motor Neurone Disease Register. J Neurol Neurosurg Psychiatry 2009, 80(1): 84-87.
[41]
Neudert C, Wasner M, Borasio GD. Individual quality of life is not correlated with health-related quality of life or physical function in patients with amyotrophic lateral sclerosis. J Palliat Med 2004, 7(4): 551-557.
[42]
Drevets WC, Furey ML. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry 2010, 67(5): 432-438.